Hemagen Diagnostics Inc
Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its human diagnostics products also comprise Universal IFA components; supplies, controls… Read more
Hemagen Diagnostics Inc (HMGN) - Total Assets
Latest total assets as of September 2012: $2.44 Million USD
Based on the latest financial reports, Hemagen Diagnostics Inc (HMGN) holds total assets worth $2.44 Million USD as of September 2012.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hemagen Diagnostics Inc - Total Assets Trend (1993–2012)
This chart illustrates how Hemagen Diagnostics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hemagen Diagnostics Inc - Asset Composition Analysis
Current Asset Composition (September 2012)
Hemagen Diagnostics Inc's total assets of $2.44 Million consist of 85.8% current assets and 14.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.7% |
| Accounts Receivable | $587.52K | 24.1% |
| Inventory | $1.36 Million | 55.8% |
| Property, Plant & Equipment | $282.31K | 11.6% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1993–2012)
This chart illustrates how Hemagen Diagnostics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hemagen Diagnostics Inc's current assets represent 85.8% of total assets in 2012, an increase from 77.6% in 1993.
- Cash Position: Cash and equivalents constituted 2.7% of total assets in 2012, down from 20.4% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1993.
- Asset Diversification: The largest asset category is inventory at 55.8% of total assets.
Hemagen Diagnostics Inc Competitors by Total Assets
Key competitors of Hemagen Diagnostics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Hemagen Diagnostics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Hemagen Diagnostics Inc generates 1.65x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hemagen Diagnostics Inc is currently not profitable relative to its asset base.
Hemagen Diagnostics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.07 | 1.61 | 2.43 |
| Quick Ratio | 0.38 | 0.65 | 1.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $145.06K | $ 923.61K | $ 2.25 Million |
Hemagen Diagnostics Inc - Advanced Valuation Insights
This section examines the relationship between Hemagen Diagnostics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -15.4% |
| Total Assets | $2.44 Million |
| Market Capitalization | $0.97 USD |
Valuation Analysis
Below Book Valuation: The market values Hemagen Diagnostics Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hemagen Diagnostics Inc's assets decreased by 15.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hemagen Diagnostics Inc (1993–2012)
The table below shows the annual total assets of Hemagen Diagnostics Inc from 1993 to 2012.
| Year | Total Assets | Change |
|---|---|---|
| 2012-09-30 | $2.44 Million | -15.43% |
| 2011-09-30 | $2.89 Million | -14.33% |
| 2010-09-30 | $3.37 Million | -9.33% |
| 2009-09-30 | $3.72 Million | -21.99% |
| 2008-09-30 | $4.77 Million | +15.27% |
| 2007-09-30 | $4.14 Million | -5.78% |
| 2006-09-30 | $4.39 Million | -17.78% |
| 2005-09-30 | $5.34 Million | -5.12% |
| 2004-09-30 | $5.63 Million | -13.28% |
| 2003-09-30 | $6.49 Million | -7.63% |
| 2002-09-30 | $7.02 Million | -16.24% |
| 2001-09-30 | $8.38 Million | -23.31% |
| 2000-09-30 | $10.93 Million | -10.40% |
| 1999-09-30 | $12.20 Million | -23.75% |
| 1998-09-30 | $16.00 Million | +39.13% |
| 1997-09-30 | $11.50 Million | -2.54% |
| 1996-09-30 | $11.80 Million | +61.64% |
| 1995-09-30 | $7.30 Million | +48.98% |
| 1994-09-30 | $4.90 Million | 0.00% |
| 1993-09-30 | $4.90 Million | -- |